

## Special Issue

# Tumor Microenvironment and Exacerbation Mechanism in Multiple Myeloma

### Message from the Guest Editor

Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells with M-protein production. Novel agents have prolonged survival in MM patients, although the disease remains incurable in the majority. Thus, new strategies are needed for the treatment of refractory MM patients and to seek a cure. To develop new treatments, it is crucial to elucidate the precise mechanisms of tumor growth and exacerbation in the myeloma microenvironment. The focus of this Special Issue is therefore on the tumor microenvironment and exacerbation mechanisms, i.e., drug resistance, proliferative signaling, immune evasion, etc., involved in aggressive disease behavior in refractory MM, leading to better management of those patients with the development of new treatment strategies.

---

### Guest Editor

Prof. Dr. Hideto Tamura

1. Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, Minamikoshigaya, Koshigaya-shi 343-8555, Saitama, Japan
2. Division of Hematology, Department of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-0086, Japan

---

### Deadline for manuscript submissions

closed (28 February 2021)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/48212](https://mdpi.com/si/48212)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)